SwePub
Sök i LIBRIS databas

  Extended search

L773:2352 3026
 

Search: L773:2352 3026 > (2021) > Severe toxicity fre...

  • Andrés-Jensen, LivCopenhagen Univ Hosp, Rigshosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, Denmark (author)

Severe toxicity free survival : physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-453068
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-453068URI
  • https://doi.org/10.1016/S2352-3026(21)00136-8DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • 5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritised severe toxicities are based on generic considerations of relevance to any other cancer diagnosis and age group.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Attarbaschi, AndisheMed Univ Vienna, St Anna Childrens Hosp, Dept Pediat Hematol Oncol, Vienna, Austria (author)
  • Bardi, EditMed Univ Vienna, St Anna Childrens Hosp, Dept Pediat Hematol Oncol, Vienna, Austria; Kepler Univ Clin, Dept Pediat Oncol & Immunol, Linz, Austria (author)
  • Barzilai-Birenboim, ShlomitSchneider Childrens Med Ctr Israel, Dept Pediat Hematol Oncol, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel (author)
  • Bhojwani, DeepaUniv Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pediat,Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA (author)
  • Hagleitner, Melanie M.Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands (author)
  • Halsey, ChristinaUniv Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Wohl Canc Res Ctr, Glasgow, Lanark, Scotland; Royal Hosp Children, Childrens Haematooncol Unit, Glasgow, Lanark, Scotland (author)
  • Harila-Saari, ArjaUppsala universitet,Barnneurologi/Barnonkologi(Swepub:uu)arjha456 (author)
  • van Litsenburg, Raphaele R. L.Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands (author)
  • Hudson, Melissa M.St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA (author)
  • Jeha, Sima (author)
  • Kato, MotohiroUniv Tokyo, Dept Pediat, Tokyo, Japan (author)
  • Kremer, LeontienPrincess Maxima Ctr Pediat Oncol, Utrecht, Netherlands (author)
  • Mlynarski, WojciechMed Univ Lodz, Dept Pediat Oncol & Hematol, Lodz, Poland (author)
  • Möricke, AnjaChristian Albrechts Univ Kiel, Univ Med Ctr Schleswig Holstein, Dept Pediat, Kiel, Germany (author)
  • Pieters, RobPrincess Maxima Ctr Pediat Oncol, Utrecht, Netherlands (author)
  • Piette, CarolineUniv Hosp Liege, Dept Paediat, Liege, Belgium; Univ Liege, Liege, Belgium (author)
  • Raetz, ElizabethNYU, Langone Med Ctr, Dept Pediat, New York, NY USA (author)
  • Ronceray, LeilaMed Univ Vienna, St Anna Childrens Hosp, Dept Pediat Hematol Oncol, Vienna, Austria (author)
  • Toro, ClaudiaRoyal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia (author)
  • Valsecchi, Maria GraziaUniv Milan, Sch Med & Surg, Bicocca Ctr Bioinformat Biostat & Bioimaging, Monza, Italy (author)
  • Vrooman, Lynda M.Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA (author)
  • Weinreb, SigalHadassah Hebrew Univ, Med Ctr, Dept Pediat Hematol Oncol, Jerusalem, Israel (author)
  • Winick, NaomiUniv Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA (author)
  • Schmiegelow, KjeldCopenhagen Univ Hosp, Rigshosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark (author)
  • Copenhagen Univ Hosp, Rigshosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, DenmarkMed Univ Vienna, St Anna Childrens Hosp, Dept Pediat Hematol Oncol, Vienna, Austria (creator_code:org_t)

Related titles

  • In:The Lancet Haematology: Elsevier8:7, s. E513-E5232352-3026

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view